Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations
about
Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiologyCommon variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variationsABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approachesMutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.Mutation of the ATP cassette binding transporter A1 (ABCA1) C-terminus disrupts HIV-1 Nef binding but does not block the Nef enhancement of ABCA1 protein degradation.Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.Intragenic suppressing mutations correct the folding and intracellular traffic of misfolded mutants of Yor1p, a eukaryotic drug transporter.Key Role of Human ABC Transporter ABCG2 in Photodynamic Therapy and Photodynamic Diagnosis.The challenge of exploiting ABCG2 in the clinic.Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patientsIn Vitro Screening of Environmental Chemicals Identifies Zearalenone as a Novel Substrate of the Placental BCRP/ABCG2 Transporter.Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small moleculesGenetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein TransporterTargeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.ABCG transporters and disease.Drug transporter pharmacogenetics in nucleoside-based therapies.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.ABCG2 c.421C>A is Associated with Outcomes Following Severe Traumatic Brain Injury.In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Contrasting roles of the ABCG2 Q141K variant in prostate cancer.Serum-dependent export of protoporphyrin IX by ATP-binding cassette transporter G2 in T24 cells.Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based ChemotherapyQuantitative Evaluation of Drug Resistance Profile of Cells Expressing Wild-Type or Genetic Polymorphic Variants of the Human ABC Transporter ABCC4.Structure of the human multidrug transporter ABCG2.Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1.Metabolic Interactions of Purine Derivatives with Human ABC Transporter ABCG2: Genetic Testing to Assess Gout RiskInternational Transporter Consortium commentary on clinically important transporter polymorphisms.PharmGKB summary: very important pharmacogene information for ABCG2.Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients.Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
P2860
Q24316869-D6319FB3-DE1E-49E9-903D-76CE322DA6DDQ27015793-B758CEB0-0F39-4C94-B5D9-50AE7E31CC8BQ27851688-BFFC02EF-A4C9-4D08-8C01-22080761738DQ28485221-0494F3AA-A70B-419D-A061-F97149A36C23Q33602553-DADE5AC2-FBAB-4BFC-9306-8A6E16987114Q33718824-D9E374A3-07AF-420A-AC94-C8EF7B6FF4FEQ34146122-D6A4714D-017F-4C51-AAE6-EB997B9E3AB8Q34176588-CD0ADECB-0C84-4A73-9A45-3329730E0AE2Q34179757-FC5BB38B-1AA9-4F42-B9CB-070F31D0CF62Q34298963-E9537915-5016-49E7-A432-E162FF1D9C18Q34415050-F332547C-FEC1-4497-9BA4-C8E472DFBB6AQ34968909-D22BDBAB-8409-440D-9D61-7B2E42297A18Q35588356-B51678A3-CEDC-456E-9F24-06B158B918F5Q35655939-D1F979A1-D9B7-4B3A-8877-4C21CAA3266AQ36729796-4C879F8C-6EC3-4093-AB34-86F3111B279DQ36733503-4F97FFDB-0668-4C2F-97FE-FB36243594ECQ36923104-AA2CF7B3-9D65-476A-AB3C-6980669B670BQ37099947-25BF6F76-49D8-4A94-A07F-9F806F38AF65Q37760954-D1D59B5C-9C48-433A-A42E-7DCF50424ECEQ37876401-F20B9445-7BA3-479E-9CD2-A55A48169BFBQ38071700-FA99361F-9538-4134-8A44-E49141C5A1D9Q38207943-AA6817D3-46FA-4B9C-855D-4C61EA2047F2Q38379295-3CDD6C0A-E2A9-461B-85B9-5CD0B28D1BBCQ38651433-DD7CE343-F1FF-4052-BBA3-DB8A986A1E18Q38838936-055DC269-FD29-45D5-ABBC-8A76150AC489Q38888369-7A975C24-0B9F-4FCA-A2BC-45016BB32A47Q38903771-38794F4C-334B-4EB6-A12F-15F46C26AD9BQ39508447-7BCA1501-0562-42B6-B7D0-EBD14D5A0CA2Q41075251-9325ADCF-128E-44D3-BE3A-3F464F41BE26Q41182056-BCD1E99B-009E-46A4-B918-59467F705CA4Q41597764-D75847FB-4F4A-401D-B086-735B0238E058Q42132520-233D127A-DF65-4AA1-B8A4-3C22D7806D10Q42839649-13D0B2A0-F296-481E-B6BE-3DF43E9E5A20Q45082643-C81D1329-F53A-4BFB-80A6-926D74B2C3BCQ46018199-7986FAAC-CBFD-4BF9-A42C-A9EB48B597FFQ46109720-18A28C15-C93E-4675-A220-751A17EBF5FFQ46788822-BFF88BB5-DD4B-4203-8E4E-465CA1C94237Q48107672-E05364D3-CAB7-4493-8F76-AB7403EB9659Q50635804-00E44F0C-42E8-4960-B88F-768FAA4C5364Q51396523-FE66BEEF-BA3E-45B1-9118-C74F8FE86638
P2860
Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Major SNP (Q141K) variant of h ...... l and proteasomal degradations
@en
Major SNP
@nl
type
label
Major SNP (Q141K) variant of h ...... l and proteasomal degradations
@en
Major SNP
@nl
prefLabel
Major SNP (Q141K) variant of h ...... l and proteasomal degradations
@en
Major SNP
@nl
P2093
P2860
P1476
Major SNP (Q141K) variant of h ...... l and proteasomal degradations
@en
P2093
Hiroshi Nakagawa
Kanako Wakabayashi
Tomoka Furukawa
Toshihisa Ishikawa
Yoichi Osawa
Yoshihiro Morishima
P2860
P304
P356
10.1007/S11095-008-9752-7
P577
2008-10-29T00:00:00Z